Mediators of Inflammation
Volume 2019 (2019), Article ID 8597159, 9 pages
https://doi.org/10.1155/2019/8597159

Research Article

Melatonin Inhibits Lipopolysaccharide-Induced Inflammation and Oxidative Stress in Cultured Mouse Mammary Tissue

Guang-Min Yu and Wen Tan

Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China

Correspondence should be addressed to Guang-Min Yu; gmyu@gdut.edu.cn and Wen Tan; went@gdut.edu.cn

Received 12 July 2018; Revised 30 September 2018; Accepted 11 November 2018; Published 12 February 2019

Academic Editor: Elaine Hatanaka

Copyright © 2019 Guang-Min Yu and Wen Tan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

To determine whether melatonin can protect cultured mouse mammary tissue from lipopolysaccharide- (LPS-) induced damage, we investigated the effects of melatonin on the mRNA and protein levels of proinflammatory cytokines and chemokines in LPS-stimulated mammary tissue in vitro. This study also examined the IgG level in both cultured mammary tissue and the culture medium. In addition, we investigated the potential benefits of melatonin on the expression of antioxidant relative genes following LPS treatment in cultured mammary tissue and evaluated ROS level in the culture medium. The results demonstrate that melatonin inhibited the mRNA expression of TNF-α, IL-1β, IL-6, CXCL1, MCP-1, and RANTES and the production of these cytokines and chemokines and IgG in LPS-stimulated mouse mammary tissue in vitro. In addition, melatonin increased Nrf2 but decreased iNOS and COX-2 mRNA expression after LPS stimulation. Similarly, the decreased level of dityrosine in the culture medium was increased by treatment with melatonin, while increased nitrite level was suppressed. This study confirms that melatonin inhibited LPS-induced inflammation and oxidative stress in cultured mouse mammary tissue. It might contribute to mastitis therapy while treating antibiotic resistance.

1. Introduction

Mastitis develops in 5–33% of women at some point during lactation [1]. It is important for two main reasons [2]. Firstly, mastitis reduces milk production and alters the cellular composition of milk. Secondly, it destroys local defenses within the breast itself. Mastitis is also an enormous risk factor causing vertical transmission of infections [3]. The condition may even develop to give rise to a local abscess [4].

Gram-negative bacteria are the most frequent causative agents of mastitis [5]. Lipopolysaccharide (LPS) is considered to be an important risk factor for the mammary cell inflammation [6]. It has been reported that inflammatory cytokines and chemokines play an important role in mastitis pathogenesis [7, 8]. The levels of these cytokines and chemokines increased in Gram-negative bacteria infection and LPS-infused mammary glands [9], which induces the migration of leukocytes [10] and the production of acute-phase proteins [11]. Following an inflammatory stimulus, reactive oxygen species (ROS) were produced and cause the cells damage [12].

Melatonin was first isolated from bovine pineal gland more than half a century ago [13]. It is the main chronobiotic hormone that regulates the circadian rhythms and seasonal changes in vertebrate physiology via its daily nocturnal increase in the blood [14]. The remarkable functional versatility of melatonin is reflected in its wide distribution within phylogenetically distant organisms including bacteria, protista, invertebrates and vertebrates, algae, plants, and fungi and is also found in various edibles, such as vegetables, fruits, seeds, and seafood [15, 16]. Melatonin shows multiple biological functions, such as antioxidant [17, 18], oncostatic [19], antiaging [20], chronobiotic actions [21], female reproduction [22, 23], innate immunity [24, 25], abiotic stress resistance [26], anticancer [27, 28], and antiradiative effects [29].

Previous studies have shown the ability of melatonin to repress proinflammatory cytokine and chemokine level and reduce oxidative stress in several experimental inflammations, including mastitis models [30–32]. Difference from the in vivo experiments and purified cells, the novelty of the present study is that we investigated LPS-stimulated mouse mammary tissue in vitro, which we try to mimic the local immunity. A series of experiments were then conducted to investigate the effect of melatonin under this situation. We evaluated the effects of melatonin on the mRNA and protein levels of proinflammatory cytokines and chemokines after LPS treatment. This study also examined the IgG level in both cultured mammary tissue and the culture medium. In addition, we investigated the potential benefits of melatonin on the expression of antioxidant relative genes following LPS treatment in cultured mammary tissue and evaluated ROS level in the culture medium.

2. Materials and Methods

2.1. Animals

Sea:ICR mice (8 wk old) were fed with standard laboratory chow and water ad libitum and kept under controlled conditions of temperature (24 ± 1°C), relative humidity (40–80%), and light (16 h light : 8 h dark cycle). Mice were treated in accordance with the regulations of SAC/TC 281 for animal experiments. Mice were placed into groups, with one male and one female as a couple. Eight days after the birth of the litter (a litter of at least 6 pups is required for adequate lactation) [33], the female mice were euthanatized by decapitation under anesthesia with intraperitoneal administration of pentobarbital sodium (Somnopentyl; Kyoritsu Seiyaku Co., Tokyo, Japan).

2.2. Tissue Culture

Mouse mammary tissue was prepared as previously described [34]. Briefly, about 2 g of mammary tissue was minced into small pastes (approximately 1 mm cubes). It was centrifuged three times at 250 g for 5 min each time. The small pieces of mammary gland were suspended in four 36 mm culture plates, each containing about 125 mg tissue and 2.5 mL DMEM/F12 containing 15% KnockOut™ serum replacement (Gibco BRL), 1% nucleosides (Millipore Co., Billerica, MA, USA), 1% nonessential amino acids (Gibco BRL), 1 mM sodium pyruvate (Gibco BRL), and 1% antibiotic-antimycotic mixed stock solution (Nacalai Tesque Inc., Kyoto, Japan). They were cultured at 37°C with 5% CO₂. Melatonin (5 mg) was dissolved in 100 μL of ethanol as the stock solution. In this study, melatonin and LPS (ALX-581-014-L001; Enzo Life Sciences, Farmingdale, NY, USA) were added into DMEM/F12 culture medium simultaneously to give final concentrations of 10 μg/mL [31, 32] and 100 ng/mL [30], respectively. Mammary tissue was cultured for 6 h. Melatonin-untreated tissue containing ethanol as the solvent at the same concentration (0.08%, w/w) used in the tests were used as a negative control.

2.3. qRT-PCR

Total RNA was extracted using NucleoSpin RNA (Macherey-Nagel Inc., Düren, Germany) according to the manufacturer’s protocol. It was then quantified by measuring absorbance at 260 nm and reverse transcribed by ReverTra Ace (Toyobo Co. Ltd., Osaka, Japan). Quantitative RT-PCR (qRT-PCR) was performed by KOD SYBR qPCR Mix (Toyobo Co. Ltd.) on Applied Biosystems StepOne Real-Time PCR System (Life Technologies Co., Darmstadt, Germany). The qPCR mixture consisted of 10 μL KOD SYBR qPCR Mix, 0.5 μM forward and reverse primers, 0.4 μL ROX Reference Dye, 2 μL template, and ddH₂O was added to a total volume of 20 μL. The parameters were as follows: initial denaturation at 98°C for 2 min; followed by 40 cycles of denaturation at 98°C for 10 s, annealing at 55–64°C for 10 s, and extension at 68°C for 1 min; melting curve from 60 to 99°C, increasing in increments of 0.5°C every 5 s. Normalization was performed using the housekeeping gene (L19) as a control. Primer sequences are listed in Table 1. Relative mRNA expression was calculated by the 2–ΔΔct method. In addition, qPCR products were resolved on 2% (w/v) agarose gels containing 0.025% (w/v) ethidium bromide and sequenced for verification.

Table 1: Primers used for qPCR.

Genes
Primer sequence (5–3)
Product size (bp)¹
Tm (°C)

L19
Forward: CTGAAGGTCAAAGGGAATGTG
196
60

Reverse: GGACACAGTCTTGATGATCTC

TNF-α
Forward: AGTCCGGGCAGGTCTACTTT
422
60

Reverse: GCACCTCAGGGAAGAATCTG

IL-1β
Forward: GGAATGACCTGTTCTTTGAAGTT
345
60

Reverse: GGCTCCGAGATGAACAACAAAA

IL-6
Forward: CCGGAGAGGAGACTTCACAG
421
60

Reverse: GGAAATTGGGGTAGGAAGGA

CXCL1
Forward: AAGATGCTAAAAGGTGTCCCCA
389
55

Reverse: CTCCCACACATGTCCTCACC

MCP-1
Forward: GGTCCCTGTCATGCTTCTGG
236
64

Reverse: CCTTCTTGGGGTCAGCACAG

RANTES
Forward: ATATGGCTCGGACACCACTC
242
62

Reverse: GGGAAGCGTATACAGGGTCA

Nrf2
Forward: CTTTAGTCAGCGACAGAAGGAC
227
62

Reverse: AGGCATCTTGTTTGGGAATGTG

iNOS
Forward: GCATGGACCAGTATAAGGCAAGAC
222
64

Reverse: GCATGGACCAGTATAAGGCAAGAC

COX-2
Forward: AGACATCCTGATCCTGGTTT
197
60

Reverse: GTTCAATGGGCTGGAAGACA

¹SYBR qPCR mix allows amplicon size of products in the present study [35, 36]. Abbreviation: L19: ribosomal protein L19 (housekeeping gene); TNF-α: tumor necrosis factor-α; IL: interleukin; CXCL: chemokine CXC motif ligand; MCP-1: monocyte chemotactic protein 1; RANTES: regulated upon activation, normal T-cell expressed and secreted; Nrf2: nuclear factor E2-related factor; iNOS: inducible nitric oxide synthase; COX-2: cyclooxygenase-2.

2.4. Western Blot Analysis

Protein sample from cultured mouse mammary tissue was prepared by homogenization in whole tissue extract buffer and then diluted by the same volume of 2×SDS sample buffer [37]. Equal amounts of protein (20 μg/lane) were resolved by SDS polyacrylamide gel (10%) electrophoresis and transferred to Immobilon-P nylon membrane (Millipore Co.). The membrane was blocked in Tris-buffered saline and Tween 20 (TBST: 10 mM Tris, pH 7.5; 150 mM NaCl; and 0.05% Tween 20), containing 5% (w/v) nonfat Carnation instant milk (Nestle, Solon, OH). Blot was incubated with primary antibody (1 : 10,000 of anti-β-actin antibody, AC74, Sigma-Aldrich Chemical Co., St. Louis, MO, USA) overnight at 4°C. After washing in TBST, it was incubated with horseradish peroxidase- (HRP-) conjugated secondary antibody (1 : 5000 of donkey anti-mouse IgG, Sigma-Aldrich Chemical Co.) for 1 hour at room temperature. Then, it was visualized by using enhanced chemiluminescence Western blotting detection reagents (Amersham Pharmacia Biotech, Newark, NJ, USA) and appropriate exposure to X-ray film (Kodak, Rochester, NY, USA). Specific bands were quantified by densitometric analyses using a GelPro analyzer (Media Cybernetics, Bethesda, MD, USA).

2.5. ELISA

Culture medium was precleared by centrifugation at 3000 g for 20 min and stored at −20°C. The level of inflammatory cytokines (TNF-α, IL-1β, and IL-6) and chemokines (CXCL1, MCP-1, and RANTES) in duplicate samples of culture medium was measured with competitive enzyme-linked immunosorbent assay (ELISA) kits, according to the manufacturer’s instructions (R&D Systems Inc., Minneapolis, MN, USA). The details of sensitivity and coefficient variation are listed in Table 2. The attenuance of the microplate was read at 450 nm.

Table 2: The sensitivity and coefficient variation of ELISA kits.

Names
Sensitivity (pg/mL)
Assay range (pg/mL)
Intra-assay CV (%)
Interassay CV (%)

TNF-α
7.21
10.9–700
2.7–3.1
6.2–8.8

IL-1β
4.8
12.5–800
3–7.5
5.7-8.4

IL-6
1.8
7.8–500
3.5-6.7
6.1–8.9

CXCL1
2
15.6–1000
3.1–5.4
3–9.8

MCP-1
2
15.6–1000
5.1–8.3
4.6-7.3

RANTES
2
7.8–500
1.8–3.7
5.1–8

The level of dityrosine in duplicate samples of tissue culture medium was determined by a competitive ELISA kit (JaICA, Shizuoka, Japan), according to the manufacturer’s instructions. It was calculated with reference to a standard curve that typically ranged from 0.05 to 12 μM.

2.6. The Griess Reaction

Nitrite concentration in the culture medium was measured using a nitrite colorimetric assay kit (Dojindo, Tokyo, Japan) based on the Griess reaction. It was determined by spectrophotometric analysis at 570 nm (Model 680 microplate 176 reader S/N 22002; Bio-Rad Laboratories, Hercules, CA, USA) with reference to a standard curve.

2.7. Statistics Analysis

Statistical analyses were carried out by one-way ANOVA followed by Duncan’s multiple-range test (StatView; Abacus Concepts Inc., Berkeley, CA, USA). Data are expressed as mean ± S.D. of 6 independent experiments. was considered statistically significant.

3. Results

LPS caused substantial increase in the mRNA level of the inflammatory cytokines TNF-α, IL-1β, and IL-6 in cultured mouse mammary tissue (, Figures 1(a)–1(c)). Addition of melatonin significantly decreased TNF-α, IL-1β, and IL-6 mRNA level after LPS stimulation (). With regard to the inflammatory chemokines, LPS treatment markedly increased CXCL1, MCP-1, and RANTES mRNA level (, Figures 1(d)–1(f)); melatonin clearly suppressed the increase in CXCL1, MCP-1, and RANTES mRNA expression after LPS treatment ().

(a)

(b)

(c)

(d)

(e)

(f)

Figure 1: Effect of melatonin on relative mRNA level of inflammatory cytokines and chemokines in LPS-stimulated mouse mammary tissue. (a) Effect of melatonin on relative mRNA level of TNF-α. (b) Effect of melatonin on relative mRNA level of IL-1β. (c) Effect of melatonin on relative mRNA level of IL-6. (d) Effect of melatonin on relative mRNA level of CXCL1. (e) Effect of melatonin on relative mRNA level of MCP-1. (f) Effect of melatonin on relative mRNA level of RANTES. Control: containing ethanol as the solvent at the same concentration used in the tests. LPS: a working concentration 100 ng/mL LPS. Mel: a working concentration 10 μg/mL melatonin. LPS+Mel: final concentrations of 100 ng/mL LPS and 10 μg/mL melatonin. Values with different letters differ significantly ().

LPS stimulation significantly increased the production of the inflammatory cytokines TNF-α, IL-1β, and IL-6 in the culture medium (, Figures 2(a)–2(c)). When present at melatonin, LPS-stimulated TNF-α, IL-1β, and IL-6 level was markedly suppressed (). In addition, the LPS-induced increase in chemokines (CXCL1, MCP-1, and RANTES) was significantly inhibited by melatonin (, Figures 2(d)–2(f)). Surprisingly, the administration of melatonin also significantly increased the basic level of IL-1β, CXCL1, and MCP-1 (, Figures 2(b)–2(e)).

(a)

(b)

(c)

(d)

(e)

(f)

Figure 2: Effect of melatonin on inflammatory cytokine and chemokine expression in LPS-stimulated mouse mammary tissue. (a) Effect of melatonin on TNF-α expression. (b) Effect of melatonin on IL-1β expression. (c) Effect of melatonin on IL-6 expression. (d) Effect of melatonin on CXCL1 expression. (e) Effect of melatonin on MCP-1 expression. (f) Effect of melatonin on RANTES expression. Control: containing ethanol as the solvent at the same concentration used in the tests. LPS: a working concentration 100 ng/mL LPS. Mel: a working concentration 10 μg/mL melatonin. LPS+Mel: final concentrations of 100 ng/mL LPS and 10 μg/mL melatonin. Values with different letters differ significantly (P < 0.05).

Results of Western blot show that LPS significantly increased the protein level of IgG in cultured mammary tissue and the culture medium (, Figure 3). Both of them were markedly inhibited by melatonin administration ().

(a)

(b)

(c)

(d)

Figure 3: Effect of melatonin on IgG level. (a) Effect of melatonin on the expression of IgG in LPS-stimulated mouse mammary tissue. IgG protein was analyzed by Western blotting. (b) Relative abundance of IgG protein in LPS-stimulated mouse mammary tissue. Proteins were normalized with β-actin. (c) Effect of melatonin on the production of IgG in tissue culture medium. IgG protein was analyzed by Western blotting. (d) Relative abundance of IgG protein in tissue culture medium. Control: containing ethanol as the solvent at the same concentration used in the tests. LPS: a working concentration 100 ng/mL LPS. Mel: a working concentration 10 μg/mL melatonin. LPS+Mel: final concentrations of 100 ng/mL LPS and 10 μg/mL melatonin. Values with different letters differ significantly ().

As shown in Figure 4(a), LPS significantly inhibited the level of Nrf2 mRNA in cultured mammary tissue (). Addition of melatonin eliminated this inhibiting effect. While the level of iNOS and COX-2 mRNA was substantially increased by LPS stimulation (), melatonin significantly suppressed these effects (, Figures 4(b) and 4(c)).

(a)

(b)

(c)

Figure 4: Effect of melatonin on relative mRNA level of antioxidant relative genes in LPS-stimulated mouse mammary tissue. (a) Effect of melatonin on relative mRNA level of Nrf2. (b) Effect of melatonin on relative mRNA level of iNOS. (c) Effect of melatonin on relative mRNA level of COX-2. Control: containing ethanol as the solvent at the same concentration used in the tests. LPS: a working concentration 100 ng/mL LPS. Mel: a working concentration 10 μg/mL melatonin. LPS+Mel: final concentrations of 100 ng/mL LPS and 10 μg/mL melatonin. Values with different letters differ significantly ().

To evaluate oxidative stress, the level of dityrosine in the culture medium was determined by ELISA; it was substantially decreased by LPS stimulation (), but this effect was inhibited by treatment with melatonin (Figure 5(a)). The nitrite level in the supernatants of treated cultured mammary tissue was measured by the Griess reaction. Result showed that LPS markedly increased the production of nitrite (, Figure 5(b)). As expected, melatonin significantly suppressed the increase in nitrite level ().

(a)

(b)

Figure 5: Effect of melatonin on the level of oxidative stress in tissue culture medium. (a) Effect of melatonin on the production of dityrosine. (b) Effect of melatonin on the production of nitrite. Control: containing ethanol as the solvent at the same concentration used in the tests. LPS: a working concentration 100 ng/mL LPS. Mel: a working concentration 10 μg/mL melatonin. LPS+Mel: final concentrations of 100 ng/mL LPS and 10 μg/mL melatonin. Values with different letters differ significantly ().

4. Discussion

Since antibiotics have been used so widely and for so long, antibiotic resistance has become a major public health threat and it is growing [38]. Some beneficial effects of the currently used alternatives to antibiotics, i.e., probiotics [39], prebiotics [40, 41], organic acids [42], and phytogenics [43] on health have been well studied. In recent years, the anti-inflammatory effect of melatonin has been highly focused on [30–32]. The present study confirms that melatonin inhibited production of proinflammatory cytokines, chemokines, and IgG in LPS-stimulated mouse mammary tissue in vitro. In addition, results show that LPS-induced oxidative stress was also diminished by melatonin.

Previous studies attest to the anti-inflammatory activity of melatonin both in vivo and in vitro. Melatonin inhibited IL-6 mRNA expression and diminished oxidative damage after venous infusion of LPS and peptidoglycan in rats [44] and also reduced the levels of TNF-α, IL-1β, and oxidative stress mediators in different regions of rat brains after intracerebroventricular administration of LPS [45]. In pregnant mice, melatonin suppressed LPS-induced increases in TNF-α level in the maternal serum and fetal brain [46]. In addition, melatonin reduced TNF-α, IL-1β, IL-6 levels and decreased the number of apoptotic neurons after intraventricular Klebsiella pneumoniae injection in rats [47]. Further, it has been observed that the expression of TNF-α, IL-1β, IL-6, and IL-8 mRNA in LPS-stimulated RAW264.7 cells was inhibited by melatonin treatment [48]. Beneficial effects were also observed when melatonin was administered to LPS-stimulated granulosa cells of the quail in vitro. In that case, melatonin decreased LPS-induced mRNA expression of IL-1β, IL-6, IL-8, and suppressed oxidative stress level [32].

With regard to the mechanism of anti-inflammation, melatonin modulated TLR4-mediated inflammation through MyD88- and TRIF-dependent signaling pathways in LPS-stimulated RAW264.7 cells [48]. Melatonin also inhibited matrix metalloproteinase-9 activation in the LPS-stimulated RAW264.7 and BV2 cells by decreasing NF-κB binding activity and translocation [49]. Focusing on mastitis model, a pretty important work has been done by Boulanger et al. [50]. They used a mammary epithelial cell line to evaluate melatonin on bovine neutrophil-induced oxidative stress following LPS stimulation. It is reported that melatonin could also inhibit LPS-induced inflammatory responses by activating peroxisome proliferator-activated receptor-γ in mouse mammary epithelial cells [30]. A recent study conducted by the authors indicates that melatonin suppressed the LBP–CD14–TLR4 signaling pathway in bovine mammary epithelial cells, which attenuated the LPS-stimulated increase in proinflammatory cytokines, chemokines, and positive acute-phase proteins at mRNA level [31]. The results of the present study proved that melatonin decreased the level of oxidative stress and the production of proinflammatory cytokines, chemokines, and IgG in LPS-stimulated mouse mammary tissue in vitro, which mimicked the local immunity.

It is interesting to notice that besides the effect that melatonin inhibiting the LPS-induced increases in proinflammatory cytokines and chemokines, it also significantly increased the basal level of some of them, such as IL-1β, CXCL1, and MCP-1. Results in this study are consistent with some previous studies that reported effects of melatonin under basal and immunosuppressed conditions in vivo [51, 52]. In fact, as an immune modulator, melatonin can exert both pro- and anti-inflammatory effects, which seems to largely depend on the cells and systems studied, and especially to the grade of inflammation. The proinflammatory effect seems to be observed under basal condition, whereas the anti-inflammatory effect is observed in the presence of high-grade inflammation [53]. Thus, melatonin appears to act as a buffer, allowing the immune system to respond to infections while attenuating serious damage in high-grade inflammation [16]. It is also thought that melatonin may promote the early stages of inflammation but suppress the sustained response to prevent chronic inflammatory disease [54].

5. Conclusions

The present study confirms that melatonin inhibited production of TNF-α, IL-1β, IL-6, CXCL1, MCP-1, RANTES, and IgG in LPS-stimulated mouse mammary tissue in vitro. In addition, melatonin increased Nrf2 but decreased iNOS and COX-2 mRNA expression after LPS stimulation. Similarly, the decreased level of dityrosine in the culture medium was increased by treatment with melatonin, while increased nitrite level was suppressed. Generally, melatonin inhibited LPS-induced inflammation and oxidative stress in cultured mouse mammary tissue, which mimicked the local immunity.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

This study was supported in part by One Hundred Project of Guangdong University of Technology (no. 220418085).

References

World Health Organization, “Mastitis: causes and management,” Tech. Rep., No. WHO/FCH/CAH/00.13, Department of Child and Adolescent Health and Development, WHO, Geneva, Switzerland, 2000.

O. Wellnitz, P. Reith, S. C. Haas, and H. H. D. Meyer, “Immune relevant gene expression of mammary epithelial cells and their influence on leukocyte chemotaxis in response to different mastitis pathogens,” Veterinární Medicína, vol. 51, no. 4, pp. 125–132, 2006.

C. A. Michie and J. W. Gilmour, “Breastfeeding and viral transmission: risks, benefits and treatments,” Journal of Tropical Pediatrics, vol. 46, no. 5, pp. 256-257, 2000.

C. Michie, F. Lockie, and W. Lynn, “The challenge of mastitis,” Archives of Disease in Childhood, vol. 88, no. 9, pp. 818–821, 2003.

L. K. Fox, “Prevalence, incidence and risk factors of heifer mastitis,” Veterinary Microbiology, vol. 134, no. 1-2, pp. 82–88, 2009.

S. Schmitz, M. W. Pfaffl, H. H. D. Meyer, and R. M. Bruckmaier, “Short-term changes of mRNA expression of various inflammatory factors and milk proteins in mammary tissue during LPS-induced mastitis,” Domestic Animal Endocrinology, vol. 26, no. 2, pp. 111–126, 2004.

K. Persson Waller, I. G. Colditz, S. Lun, and K. Östensson, “Cytokines in mammary lymph and milk during endotoxin-induced bovine mastitis,” Research in Veterinary Science, vol. 74, no. 1, pp. 31–36, 2003.

J. Zheng, A. D. Watson, and D. E. Kerr, “Genome-wide expression analysis of lipopolysaccharide-induced mastitis in a mouse model,” Infection and Immunity, vol. 74, no. 3, pp. 1907–1915, 2006.

Y. Fu, E. Zhou, Z. Wei et al., “Glycyrrhizin inhibits the inflammatory response in mouse mammary epithelial cells and a mouse mastitis model,” The FEBS Journal, vol. 281, no. 11, pp. 2543–2557, 2014.

A. Zlotnik and O. Yoshie, “Chemokines: a new classification system and their role in immunity,” Immunity, vol. 12, no. 2, pp. 121–127, 2000.

S. Hiss, M. Mielenz, R. M. Bruckmaier, and H. Sauerwein, “Haptoglobin concentrations in blood and milk after endotoxin challenge and quantification of mammary Hp mRNA expression,” Journal of Dairy Science, vol. 87, no. 11, pp. 3778–3784, 2004.

S. Reuter, S. C. Gupta, M. M. Chaturvedi, and B. B. Aggarwal, “Oxidative stress, inflammation, and cancer: how are they linked?” Free Radical Biology & Medicine, vol. 49, no. 11, pp. 1603–1616, 2010.

A. B. Lerner, J. D. Case, Y. Takahashi, T. H. Lee, and W. Mori, “Isolation of melatonin, the pineal gland factor that lightens melanocytes,” Journal of the American Chemical Society, vol. 80, no. 10, pp. 2587–2587, 1958.

R. J. Reiter, “Pineal melatonin: cell biology of its synthesis and of its physiological interactions,” Endocrine Reviews, vol. 12, no. 2, pp. 151–180, 1991.

R. Hardeland and B. Poeggeler, “Non-vertebrate melatonin,” Journal of Pineal Research, vol. 34, no. 4, pp. 233–241, 2003.

A. Carrillo-Vico, P. Lardone, N. Álvarez-Sánchez, A. Rodríguez-Rodríguez, and J. Guerrero, “Melatonin: buffering the immune system,” International Journal of Molecular Sciences, vol. 14, no. 4, pp. 8638–8683, 2013.

B. Poeggeler, S. Saarela, R. J. Reiter et al., “Melatonin—a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro,” Annals of the New York Academy of Sciences, vol. 738, no. 1, pp. 419-420, 1994.

R. J. Reiter, J. C. Mayo, D. X. Tan, R. M. Sainz, M. Alatorre-Jimenez, and L. Qin, “Melatonin as an antioxidant: under promises but over delivers,” Journal of Pineal Research, vol. 61, no. 3, pp. 253–278, 2016.

P. Lissoni, S. Barni, G. Tancini et al., “A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients,” Oncology, vol. 50, no. 6, pp. 399–402, 1993.

B. Poeggeler, “Melatonin, aging, and age-related diseases: perspectives for prevention, intervention, and therapy,” Endocrine, vol. 27, no. 2, pp. 201–212, 2005.

E. Peschke, I. Bähr, and E. Mühlbauer, “Experimental and clinical aspects of melatonin and clock genes in diabetes,” Journal of Pineal Research, vol. 59, no. 1, pp. 1–23, 2015.

F. Wang, X. Z. Tian, Y. H. Zhou et al., “Melatonin improves the quality of in vitro produced (IVP) bovine embryos: implications for blastocyst development, cryotolerance, and modifications of relevant gene expression,” PLoS One, vol. 9, no. 4, article e93641, 2014.

G.-M. Yu, N. Isobe, and T. Maeda, “Melatonin does not affect progesterone basal secretion but suppresses the luteinizing hormone receptor expression in granulosa cells of the Japanese quail,” The Journal of Poultry Science, vol. 54, no. 4, pp. 312–318, 2017.

A. Carrillo-Vico, J. M. Guerrero, P. J. Lardone, and R. J. Reiter, “A review of the multiple actions of melatonin on the immune system,” Endocrine, vol. 27, no. 2, pp. 189–200, 2005.

W. Zhou, X. Zhang, C. L. Zhu, Z. Y. He, J. P. Liang, and Z. C. Song, “Melatonin receptor agonists as the "perioceutics" agents for periodontal disease through modulation of Porphyromonas gingivalis virulence and inflammatory response,” PLoS One, vol. 11, no. 11, article e0166442, 2016.

N. Zhang, Q. Sun, H. Zhang et al., “Roles of melatonin in abiotic stress resistance in plants,” Journal of Experimental Botany, vol. 66, no. 3, pp. 647–656, 2015.

A. J. Moreira, R. Ordoñez, C. T. Cerski et al., “Melatonin activates endoplasmic reticulum stress and apoptosis in rats with diethylnitrosamine-induced hepatocarcinogenesis,” PLoS One, vol. 10, no. 12, article e0144517, 2015.

F. Söderquist, E. T. Janson, A. J. Rasmusson, A. Ali, M. Stridsberg, and J. L. Cunningham, “Melatonin immunoreactivity in malignant small intestinal neuroendocrine tumours,” PLoS One, vol. 11, no. 10, article e0164354, 2016.

B. Fernández-Gil, A. E. A. Moneim, F. Ortiz et al., “Melatonin protects rats from radiotherapy-induced small intestine toxicity,” PLoS One, vol. 12, no. 4, article e0174474, 2017.

G. Shao, Y. Tian, H. Wang, F. Liu, and G. Xie, “Protective effects of melatonin on lipopolysaccharide-induced mastitis in mice,” International Immunopharmacology, vol. 29, no. 2, pp. 263–268, 2015.

G. M. Yu, H. Kubota, M. Okita, and T. Maeda, “The anti-inflammatory and antioxidant effects of melatonin on LPS-stimulated bovine mammary epithelial cells,” PLoS One, vol. 12, no. 5, article e0178525, 2017.

G.-M. Yu, N. Isobe, and T. Maeda, “Protective effect of melatonin on LPS-stimulated granulosa cells in Japanese quail,” The Journal of Poultry Science, vol. 54, no. 4, pp. 319–325, 2017.

W. Barham, T. Sherrill, L. Connelly, T. S. Blackwell, and F. E. Yull, “Intraductal injection of LPS as a mouse model of mastitis: signaling visualized via an NF-κB reporter transgenic,” Journal of Visualized Experiments, no. 67, article e4030, 2012.

L. Yang, L. Y. Zhang, C. Wang, B. Wang, X. M. Wang, and S. M. Zeng, “Differential expression pattern of ISG15 in different tissue explants and cells induced by various interferons,” Microbiology and Immunology, vol. 56, no. 3, pp. 163–170, 2012.

M. Shimada, Y. Yanai, T. Okazaki et al., “Hyaluronan fragments generated by sperm-secreted hyaluronidase stimulate cytokine/chemokine production via the TLR2 and TLR4 pathway in cumulus cells of ovulated COCs, which may enhance fertilization,” Development, vol. 135, no. 11, pp. 2001–2011, 2008.

T. Kawai, N. Yanaka, J. S. Richards, and M. Shimada, “De novo-synthesized retinoic acid in ovarian antral follicles enhances FSH-mediated ovarian follicular cell differentiation and female fertility,” Endocrinology, vol. 157, no. 5, pp. 2160–2172, 2016.

Y. Guangmin, I. U. Haq, S. H. Khan, and Z. Mingsheng, “Actin filaments are necessary for FSH-induced CYP19A1 transcription in bovine granulosa cells in vitro,” Pakistan Veterinary Journal, vol. 35, no. 1, pp. 53–57, 2015.

G.-M. Yu, J.-H. Bai, Y. Liu, T. Maeda, and S. M. Zeng, “A weekly postpartum PGF2α protocol enhances uterine health in dairy cows,” Reproductive Biology, vol. 16, no. 4, pp. 295–299, 2016.

R. M. La Ragione, A. Narbad, M. J. Gasson, and M. J. Woodward, “In vivo characterization of Lactobacillus johnsonii FI9785 for use as a defined competitive exclusion agent against bacterial pathogens in poultry,” Letters in Applied Microbiology, vol. 38, no. 3, pp. 197–205, 2004.

I. A. Schepetkin and M. T. Quinn, “Botanical polysaccharides: macrophage immunomodulation and therapeutic potential,” International Immunopharmacology, vol. 6, no. 3, pp. 317–333, 2006.

M. Novak and V. Vetvicka, “β-glucans, history, and the present: immunomodulatory aspects and mechanisms of action,” Journal of Immunotoxicology, vol. 5, no. 1, pp. 47–57, 2008.

F. Van Immerseel, J. B. Russell, M. D. Flythe et al., “The use of organic acids to combat Salmonella in poultry: a mechanistic explanation of the efficacy,” Avian Pathology, vol. 35, no. 3, pp. 182–188, 2006.

S. Burt, “Essential oils: their antibacterial properties and potential applications in foods—a review,” International Journal of Food Microbiology, vol. 94, no. 3, pp. 223–253, 2004.

D. A. Lowes, N. R. Webster, M. P. Murphy, and H. F. Galley, “Antioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis,” British Journal of Anaesthesia, vol. 110, no. 3, pp. 472–480, 2013.

E. Tyagi, R. Agrawal, C. Nath, and R. Shukla, “Effect of melatonin on neuroinflammation and acetylcholinesterase activity induced by LPS in rat brain,” European Journal of Pharmacology, vol. 640, no. 1–3, pp. 206–210, 2010.

D. X. Xu, H. Wang, H. Ning, L. Zhao, and Y. H. Chen, “Maternally administered melatonin differentially regulates lipopolysaccharide-induced proinflammatory and anti-inflammatory cytokines in maternal serum, amniotic fluid, fetal liver, and fetal brain,” Journal of Pineal Research, vol. 43, no. 1, pp. 74–79, 2007.

U. I. Wu, F. D. Mai, J. N. Sheu et al., “Melatonin inhibits microglial activation, reduces pro-inflammatory cytokine levels, and rescues hippocampal neurons of adult rats with acute Klebsiella pneumoniae meningitis,” Journal of Pineal Research, vol. 50, no. 2, pp. 159–170, 2011.

M. Z. Xia, Y. L. Liang, H. Wang et al., “Melatonin modulates TLR4-mediated inflammatory genes through MyD88- and TRIF-dependent signaling pathways in lipopolysaccharide-stimulated RAW264.7 cells,” Journal of Pineal Research, vol. 53, no. 4, pp. 325–334, 2012.

C.-C. Chang, C.-H. Tien, E.-J. Lee et al., “Melatonin inhibits matrix metalloproteinase-9 (MMP-9) activation in the lipopolysaccharide (LPS)-stimulated RAW 264.7 and BV2 cells and a mouse model of meningitis,” Journal of Pineal Research, vol. 53, no. 2, pp. 188–197, 2012.

V. Boulanger, X. Zhao, and P. Lacasse, “Protective effect of melatonin and catalase in bovine neutrophil-induced model of mammary cell damage,” Journal of Dairy Science, vol. 85, no. 3, pp. 562–569, 2002.

J. Arias, E. Melean, N. Valero et al., “Effect of melatonin on lymphocyte proliferation and production of interleukin-2 (IL-2) and interleukin-1 beta (IL-1 beta) in mice splenocytes,” Investigación Clínica, vol. 44, no. 1, pp. 41–50, 2003.

C. Peña, J. Rincon, A. Pedreanez, N. Viera, and J. Mosquera, “Chemotactic effect of melatonin on leukocytes,” Journal of Pineal Research, vol. 43, no. 3, pp. 263–269, 2007.

R. Hardeland, D. P. Cardinali, G. M. Brown, and S. R. Pandi-Perumal, “Melatonin and brain inflammaging,” Progress in Neurobiology, vol. 127-128, pp. 46–63, 2015.

F. Radogna, M. Diederich, and L. Ghibelli, “Melatonin: a pleiotropic molecule regulating inflammation,” Biochemical Pharmacology, vol. 80, no. 12, pp. 1844–1852, 2010.